Drug Trial Radar · NCT07897721
A Study to Learn About the Study Medicine Called PF-08165784 in People With PIK3CA-Mutated Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
268
Planned (sponsor's estimate)
Start
Nov 9, 2026
Primary completion
Mar 22, 2030
Study completion Mar 21, 2032
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the study medicine (called PF-08165784) when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment given to stop the growth of cancer. This study also aims to find the best amount of study medication that can be given to patients. This study is seeking participants with a specific type of breast cancer called hormone receptor-positive (HR+), HER2- negative (HER2-) breast cancer, or colorectal cancer (cancer of the colon or rectum), that has a change (mutation) in a gene called PIK3CA. The cancer must be advanced or metastatic, meaning it has spread to other parts of the body or cannot be completely removed with surgery. All participants in this study will take the study medication (PF-08165784) as a tablet by mouth. The participant may take the medicine at the study clinic during study visits or at home. Treatment will be given in 28-day cycles and will continue for as long as the participant remains in the study. Depending on which part of the study participants are enrolled into, they will receive the study medication (PF-08165784) alone or in combination with other anti-cancer medications.
Conditions
- Advanced Breast Cancer
- Advanced or Metastatic Breast Cancer
- Metastatic Breast Cancer (HR+/ HER2-)
- Metastatic Colorectal Adenocarcinoma
Interventions
PF-08165784Drug
Taken by mouth (PO)
FulvestrantDrug
Selective Estrogen Receptor Degrader (SERD)
AtirmociclibDrug
Selective CDK4 inhibitor
CetuximabDrug
Monoclonal antibody (EGFR inhibitor)
LetrozoleDrug
Nonsteroidal aromatase inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation): Number of participants with Dose-Limiting Toxicities (DLT)Time frame: Baseline up to 28 days
- Part 1 (Dose Escalation): Incidence of Adverse Events (AEs)Time frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
- Part 1 (Dose Escalation): Number of participants with laboratory abnormalitiesTime frame: From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
- Part 2 (Dose Expansion): Objective Response Rate (ORR)Time frame: Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion (approximately 2 years)
Locations
5 sites in 2 countries. Site status is shown where the registry gives one.
Highlands Oncology Group, PA
Fayetteville, Arkansas
Highlands Oncology Group, PA
Rogers, Arkansas
Highlands Oncology Group, PA
Springdale, Arkansas
START Midwest, LLC
Grand Rapids, Michigan
Pan American Center for Oncology Trials, LLC- Hospital Oncológico Office
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.